Published in Nat Med on May 01, 1996
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev (2001) 5.67
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell (2006) 3.78
Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer (2010) 3.74
Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55
A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol (2006) 3.40
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15
Organoid cultures derived from patients with advanced prostate cancer. Cell (2014) 3.12
Anaplastic lymphoma kinase: signalling in development and disease. Biochem J (2009) 3.05
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell (2012) 2.89
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res (2007) 2.78
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood (2007) 2.65
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A (2003) 2.44
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42
Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol (2000) 2.41
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer (2006) 2.33
High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci (2005) 2.32
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood (2005) 2.14
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A (2002) 2.13
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood (2011) 2.11
MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature (2014) 2.11
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest (2012) 2.01
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res (2008) 1.98
Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg (2006) 1.95
Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol (2009) 1.92
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res (2009) 1.91
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med (2000) 1.89
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol (2007) 1.84
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood (2006) 1.83
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82
Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood (2012) 1.81
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst (2013) 1.75
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther (2008) 1.74
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther (2009) 1.73
EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer (2008) 1.73
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med (2011) 1.72
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A (2008) 1.71
Abl kinase inhibits the engulfment of apoptotic [corrected] cells in Caenorhabditis elegans. PLoS Biol (2009) 1.69
Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction. FEBS J (2013) 1.68
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood (2011) 1.68
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A (2010) 1.67
Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res (2011) 1.65
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther (2008) 1.65
FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol (2004) 1.63
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene (2010) 1.63
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol (2002) 1.60
Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology (2010) 1.60
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood (2013) 1.60
Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther (2010) 1.59
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag (2008) 1.59
MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines. Cancer Chemother Pharmacol (2009) 1.56
Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. Eur J Nucl Med Mol Imaging (2010) 1.55
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem (2006) 1.55
The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J (2002) 1.55
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis (2011) 1.53
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer (2010) 1.53
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med (2011) 1.52
ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell (2016) 1.50
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med (2017) 1.49
Applying the discovery of the Philadelphia chromosome. J Clin Invest (2007) 1.46
The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. Cell Commun Signal (2015) 1.46
Small gastrointestinal stromal tumor concomitant with early gastric cancer: a case report. World J Gastroenterol (2006) 1.45
gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem (2005) 1.45
Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle (2009) 1.44
Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol (2013) 1.44
MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J (2006) 1.42
Perspectives on the development of imatinib and the future of cancer research. Nat Med (2009) 1.42
A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. J Exp Med (2015) 1.42
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol (2009) 1.42
c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J (2002) 1.41
Kinome-wide Decoding of Network-Attacking Mutations Rewiring Cancer Signaling. Cell (2015) 1.38
Shifting paradigms: the seeds of oncogene addiction. Nat Med (2009) 1.37
MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell (2014) 1.36
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A (1999) 1.35
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest (2014) 1.34
Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int (2007) 1.34
Targeted therapies: how personal should we go? Nat Rev Clin Oncol (2011) 1.31
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A (2005) 1.30
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood (2009) 1.29
Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs (2011) 1.29
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood (2007) 1.27
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget (2011) 1.27
The GIST paradigm: lessons for other kinase-driven cancers. J Pathol (2010) 1.26
Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis (2010) 1.26
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Automated DNA sequencing of the human HPRT locus. Genomics (1990) 5.92
Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol (2001) 5.62
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther (2000) 5.09
Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc (1996) 4.33
IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03
Evolution from fish to mammals by gene duplication. Hereditas (1968) 3.95
The nucleotide sequence of human fibroblast interferon cDNA. Gene (1980) 3.80
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 3.77
Delimitation and properties of DNA sequences required for the regulated expression of human interferon-beta gene. Cell (1985) 3.57
Complete DNA sequence of yeast chromosome XI. Nature (1994) 3.51
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation. Proc Natl Acad Sci U S A (1981) 3.04
An atypical PKC directly associates and colocalizes at the epithelial tight junction with ASIP, a mammalian homologue of Caenorhabditis elegans polarity protein PAR-3. J Cell Biol (1998) 3.04
Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell (1979) 2.92
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst (1999) 2.81
Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res (2001) 2.79
Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol (1991) 2.71
Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest (1993) 2.64
One subspecies of the red junglefowl (Gallus gallus gallus) suffices as the matriarchic ancestor of all domestic breeds. Proc Natl Acad Sci U S A (1994) 2.64
Structure and expression of a cloned cDNA for mouse interferon-beta. J Biol Chem (1983) 2.61
Evolutionary origin of a calcium-dependent protease by fusion of genes for a thiol protease and a calcium-binding protein? Nature (1985) 2.52
Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures. J Cell Biol (2001) 2.51
Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol (1982) 2.51
Atypical protein kinase C cooperates with PAR-3 to establish embryonic polarity in Caenorhabditis elegans. Development (1998) 2.47
Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem (1996) 2.43
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res (2000) 2.43
NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol (1994) 2.40
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol (2000) 2.36
New retraction technique to allow better visualization of Calot's triangle during laparoscopic cholecystectomy. Surg Endosc (1998) 2.35
Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. Mol Cell Biol (1998) 2.32
Nerve growth factor, laminin, and fibronectin promote neurite growth in human fetal sensory ganglia cultures. J Neurosci Res (1982) 2.28
The cell polarity protein ASIP/PAR-3 directly associates with junctional adhesion molecule (JAM). EMBO J (2001) 2.28
Monophyletic origin and unique dispersal patterns of domestic fowls. Proc Natl Acad Sci U S A (1996) 2.27
Tissue-specific expression of three distinct types of rabbit protein kinase C. Nature (1987) 2.14
PAR-6 regulates aPKC activity in a novel way and mediates cell-cell contact-induced formation of the epithelial junctional complex. Genes Cells (2001) 2.13
A phorbol ester receptor/protein kinase, nPKC eta, a new member of the protein kinase C family predominantly expressed in lung and skin. J Biol Chem (1990) 2.12
EGF or PDGF receptors activate atypical PKClambda through phosphatidylinositol 3-kinase. EMBO J (1996) 2.11
Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci U S A (1997) 2.10
So much "junk" DNA in our genome. Brookhaven Symp Biol (1972) 2.09
The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. J Biol Chem (1996) 2.06
Tumor necrosis factor type alpha stimulates human endothelial cells to produce granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci U S A (1986) 2.06
Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes Cells (2000) 2.05
Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut (2005) 2.03
Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens (1999) 2.02
Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med (2001) 2.02
Simultaneous on-line DNA sequencing on both strands with two fluorescent dyes. Anal Biochem (1995) 2.01
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med (1998) 2.01
Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1992) 2.01
A new member of the protein kinase C family, nPKC theta, predominantly expressed in skeletal muscle. Mol Cell Biol (1992) 1.97
Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. Hypertension (1998) 1.96
Regression of duodenal mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. Gastroenterology (1996) 1.95
Rapid diagnosis of adenoviral conjunctivitis by PCR and restriction fragment length polymorphism analysis. J Clin Microbiol (1996) 1.94
E-cadherin mediated adhesion system in cancer cells. Cancer (1996) 1.94
Retracted Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A (1995) 1.93
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res (2000) 1.88
A novel integrin-linked kinase-binding protein, affixin, is involved in the early stage of cell-substrate interaction. J Cell Biol (2001) 1.84
Simulation model of an eyeball based on finite element analysis on a supercomputer. Br J Ophthalmol (1999) 1.83
Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res (2000) 1.81
Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem (1995) 1.81
A new technique for laparoscopic resection of a submucosal tumor on the posterior wall of the gastric fundus. Surg Endosc (1999) 1.80
A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. J Biol Chem (1984) 1.79
Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology (1996) 1.78
Endoscopic diagnosis and treatment of early colorectal cancer. World J Surg (1997) 1.77
Letter: HL-A5 and Behçet's disease. Lancet (1973) 1.76
A new member of the third class in the protein kinase C family, PKC lambda, expressed dominantly in an undifferentiated mouse embryonal carcinoma cell line and also in many tissues and cells. J Biol Chem (1994) 1.75
Human PEX19: cDNA cloning by functional complementation, mutation analysis in a patient with Zellweger syndrome, and potential role in peroxisomal membrane assembly. Proc Natl Acad Sci U S A (1999) 1.75
Structure of rhodotorucine A, a novel lipopeptide, inducing mating tube formation in Rhodosporidium toruloides. Biochem Biophys Res Commun (1978) 1.74
Dystrophin localization at presynapse in rat retina revealed by immunoelectron microscopy. Invest Ophthalmol Vis Sci (1995) 1.70
Inducer-responsive expression of the cloned human interferon beta 1 gene introduced into cultured mouse cells. Nucleic Acids Res (1982) 1.69
Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer (1997) 1.67
Serotyping of adenoviruses on conjunctival scrapings by PCR and sequence analysis. J Clin Microbiol (1999) 1.66
Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem (1997) 1.66
Enterobacter sakazakii: an emerging pathogen in powdered infant formula. Clin Infect Dis (2006) 1.63
Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem (1989) 1.63
Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine (2000) 1.63
Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods (1997) 1.62
Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine (1990) 1.62
E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res (1994) 1.61
Endoscopic screening of early esophageal cancer with the Lugol dye method in patients with head and neck cancers. Cancer (1990) 1.58
Trends in antimicrobial susceptibility among isolates of Campylobacter species in Ireland and the emergence of resistance to ciprofloxacin. Vet Rec (2002) 1.57
Original domain for the serum albumin family arose from repeated sequences. Proc Natl Acad Sci U S A (1981) 1.56
[A case of colon cancer with tension pneumothorax and empyema as a consequence of colo-pleural fistula]. Nihon Kokyuki Gakkai Zasshi (2000) 1.53
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res (2001) 1.53
Methicillin-resistant Staphylococcus aureus (MRSA) isolated from animals and veterinary personnel in Ireland. Vet Microbiol (2005) 1.52
Chronic manganese poisoning: a neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol (1986) 1.52
Primary structures of human protein kinase C beta I and beta II differ only in their C-terminal sequences. FEBS Lett (1987) 1.52
Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and abelson virus. J Exp Med (1984) 1.52
Lugol-combined endoscopic detection of minute malignant lesions of the thoracic esophagus. Ann Surg (1988) 1.52